Carla Casulo
A5064738578- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Multiple and Secondary Primary Cancers
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Cutaneous lymphoproliferative disorders research
- Biosimilars and Bioanalytical Methods
- Childhood Cancer Survivors' Quality of Life
- Sarcoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Family Support in Illness
- Acute Myeloid Leukemia Research
- Cancer Risks and Factors
- Immunotherapy and Immune Responses
- Cancer survivorship and care
- PI3K/AKT/mTOR signaling in cancer
University of Rochester
2016-2025
University of Rochester Medical Center
2015-2024
City of Hope
2022
Ospedale Papa Giovanni XXIII
2022
University of California, Irvine
2022
Dana-Farber Cancer Institute
2022
Boston University
2022
The Ohio State University
2022
Washington University in St. Louis
2022
Columbia University
2022
Twenty percent of patients with follicular lymphoma (FL) experience progression disease (POD) within 2 years initial chemoimmunotherapy. We analyzed data from the National LymphoCare Study to identify whether prognostic FL factors are associated early POD and at high risk for death.In total, 588 stage 4 received first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Two groups were defined: or less after diagnosis those without years, reference group. An...
LBA4 Background: The addition of BV to initial chemotherapy improves overall survival (OS) in adults and PFS pediatric patients (pts) with AS HL. However, frontline adds toxicity, most pts receive radiation therapy (RT), 7-20% still develop relapsed/refractory (RR) PD-1 pathway is central the pathogenesis HL blockade effective RR adult cooperative groups National Clinical Trials Network (NCTN) conducted randomized, phase 3 S1826 trial evaluate N-AVD vs BV-AVD newly diagnosed Methods:...
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel patients with R/R indolent non-Hodgkin (iNHL; N = 104), including FL and marginal zone (MZL). In primary analysis (median follow-up, 17.5 months), overall response rate (ORR) 92% (complete rate, 74%). Here, we report long-term outcomes...
Highlights•Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS).•FL patients ETF receiving autoHCT soon after treatment (≤1 year ETF; n = 123) had higher 5-year OS than those without (73% versus 60%).AbstractPatients (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) National LymphoCare Study (NLCS) to determine whether autologous...
Summary Treatment with dose‐adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab ( DA ‐ ‐R) has become the standard of care for primary mediastinal B‐cell lymphoma PMBCL ) at many institutions despite limited data in multi‐centre setting. We report a large, retrospective analysis children adults treated ‐R to characterize outcomes evaluate prognostic factors. assessed 156 patients across 24 academic centres, including 38 118 adults....
Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly the activated B-cell-like (ABC) subtype. Eastern Cooperative Oncology Group (ECOG)-ACRIN trial E1412 was a randomized phase II study comparing R2CHOP versus R-CHOP DLBCL.
To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or refractory classic Hodgkin lymphoma patients destined for an autologous stem cell transplant.
Abstract To address the current and long‐term unmet health needs of growing population non‐Hodgkin lymphoma (NHL) patients, we established Lymphoma Epidemiology Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/ ). A total 7735 newly diagnosed patients aged 18 years older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in United States. The median age diagnosis was 62 (range, 18–99). Participants came 49 US states included 538...
Background: The addition of BV to initial chemotherapy improves outcomes in adult and pediatric patients (pts) with AS HL. However, frontline adds toxicity, most pts receive radiation therapy (RT), 7%–20% still develop relapsed/refractory (RR) PD-1 pathway is central the pathogenesis HL blockade effective RR cooperative groups National Clinical Trials Network (NCTN) conducted randomized, phase 3 S1826 trial evaluate N-AVD versus BV-AVD newly diagnosed Methods: Eligible were ≥12 years (y)...
8008 Background: Advanced stage iNHL, including follicular lymphoma (FL) and marginal zone (MZL), is considered incurable as most pts experience multiple relapses (Wang, et al. Ther Adv Hematol. 2017), highlighting a need for novel therapies. Here, we present interim results from ZUMA-5, Phase 2, multicenter study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in with R/R iNHL. Methods: Adults FL (Grades 1-3a) or MZL (nodal extranodal) after ≥ 2 lines...
// Mary Pulvino 1 , Luojing Chen 2 David Oleksyn Jing Li 3 George Compitello Randy Rossi 4 Stephen Spence 5 Vijaya Balakrishnan Craig Jordan 4, 6 Brian Poligone 7 Carla Casulo Richard Burack Joel L. Shapiro 8 Steven Bernstein Jonathan W. Friedberg Raymond J. Deshaies 3, 9 Hartmut Land 1, Jiyong Zhao Department of Biomedical Genetics, University Rochester Medical Center, Rochester, NY, USA Division Allergy/Immunology and Rheumatology, Biology Biological Engineering, California Institute...
Abstract Patients with advanced‐stage follicular lymphoma (FL) who progress early after receiving first‐line therapy have poor overall survival (OS). Currently applied clinical prognostic models such as FL International Prognostic Index [FLIPI], FLIPI‐2 and PRIMA‐Prognostic [PRIMA‐PI] suboptimal sensitivity specificity to predict this prognosis subgroup. The primary objective was develop a novel model, the Evaluation (FLEX) score, identify high‐risk patients compare its performance FLIPI,...